ArticleMolecular therapy. Oncology2026
Feasibility and outcomes of decentralized point-of-care CD19 CAR T cell for relapsed large B cell lymphoma in resource-limited settings.
Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD19 chimeric antigen receptor (CAR) T cell therapy has transformed outcomes for patients with relapsed/refractory (R/R) large B cell lymphoma (LBCL), yet access to commercial products remains severely limited in low- and middle-income countries due to high cost, infrastructure requirements, and centralized manufacturing. Herein, we developed and implemented a decentralized point-of-care (POC) CAR T cell platform in Thailand using an automated closed system (CliniMACS Prodigy), integrating local manufacturing with clinical delivery. Between 2020 and 2025, 12 patients with R/R LBCL (median age 45.8 years) were treated, with a median vein-to-vein time of 12 days. Manufacturing was successful in 11 patients, while one received an out-of-specification dose. Final products demonstrated a balanced CD4:CD8 ratio and were enriched for memory T cell subsets. Cytokine release syndrome occurred in 5 patients (grade 3 in 1), and neurotoxicity in 1 patient (grade 1). At 3 months, the overall response rate was 58.3%, including 33.3% complete responses. One-year event-free and overall survival were 58.3% and 90%. The median total cost was USD 111,231. These findings demonstrate that decentralized POC CAR T cell therapy is feasible, effective, and more affordable, supporting scalable implementation in resource-limited settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.